The Latest Cardiac and Vascular News
Company builds on its expansion into deeper data analysis and predictive analytics REDWOOD CITY, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it has filed a 510(k) application for US FDA clearance for its next generation, advanced ECG analysis software. […]
REDWOOD CITY, Calif., Jan. 22, 2020 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it is finalizing its FDA filing for its next generation, advanced ECG analysis software with an expectation to file a 510(k) clearance application with the US FDA by end […]
Company Prepares for FDA Filing of New Device REDWOOD CITY, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has completed development of its ECG patch platform. An extension of the company’s award-winning Bioflux® device, Biopatch is ideal for patients with less […]
REDWOOD CITY, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will be actively pursuing the Holter market in addition to the MCT market with its Bioflux product offering, expanding its revenue growth opportunities. Bioflux is a 3 in 1 monitoring solution, […]
REDWOOD CITY, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will be expanding the scope of a previously approved clinical investigation of fetal heart rate variability (fHRV) to include maternal HRV and other key physiologic metrics […]
REDWOOD CITY, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today provided operational updates for its fiscal 2018 second quarter which ended September 30, 2018. Bioflux 1.0 sales growth and market expansion achieved a record high during the fiscal 2018 second quarter; the […]
REDWOOD CITY, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it is developing “Biopatch,” an ECG patch which it hopes to release in Q1 2019. An extension of the company’s award-winning Bioflux device, Biopatch offers an alternative to the 3-lead system […]
REDWOOD CITY, Calif., July 09, 2018 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, today provided operational updates for its fiscal 2018 first quarter which ended June 30, 2018. The Company’s premier product, Bioflux, has achieved market expansion […]
REDWOOD CITY, Calif., June 06, 2018 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, today announced that its Bioflux device has won the prestigious MedTech Breakthrough Award 2018 for Best Remote Patient Monitoring Solution. MedTech Breakthrough, an independent organization that recognizes […]
REDWOOD CITY, Calif., April 12, 2017 (GLOBE NEWSWIRE) — Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, has filed for a second and final 510(k) for the hardware portion of its Bioflux solution with the U.S. Food and Drug Administration […]
